Florida Cancer Specialists & Research Institute (FCS), an independent medical oncology/haematology practice in Florida, has established a healthcare analytics subsidiary named Vita Nova Insights.
The subsidiary is fully owned by FCS’ management services organisation, Community Oncology Revitalization Enterprise (Core Ventures).
Go deeper with GlobalData
It is dedicated to providing precision oncology insights and real-world evidence to enhance cancer research and treatment.
Over the last year, Vita Nova Insights has carried out various real-world evidence studies in collaboration with leading pharmaceutical companies worldwide.
The subsidiary’s connection with FCS physicians allows them to quickly identify and act on therapeutic challenges to improve patient outcomes.
See Also:
Vita Nova Insights, in partnership with FCS, gives physicians and clinical researchers access to FCS’ diverse range of data assets.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThese assets include practice management systems and electronic medical records (EMRs), as well as data from radiation oncology, radiology, genomics, pharmacies and laboratories.
The data is standardised and enriched with external sources to provide a comprehensive patient health overview.
Vita Nova Insights combines artificial intelligence technology and data science with its clinical oncology expertise to create insights that support clinical research, optimise patient care and convert FCS’ real-world data into valuable evidence for new therapy development and discovery.
The new subsidiary will also give FCS physicians analytic insights into next-generation sequencing tests conducted across the practice.
This is provided by the company’s in-house MolecularHelp service, which is powered by the FCS PRECISE precision-oncology platform.
FCS senior vice-president and data officer Trevor Heritage said: “Given the pace of innovation in precision-oncology, with new therapies coming to market at a rate never seen before, it is challenging for physicians to keep up.
“Vita Nova Insights analyses every genomics test result, in the context of the full patient clinical record, and alerts physicians to corresponding treatment options and associated evidence in real-time.”
